Peptide Stacking 101: Common Combinations, Risks, and How to Log Them

Stacking — using two or more compounds in a single protocol — is common in the peptide community. The theory is that carefully selected combinations produce synergistic effects. But stacking also multiplies complexity and risk.

Common stacks

GH secretagogue stack

• GHRH analogue (Mod GRF / CJC-1295 no DAC) + GH secretagogue (ipamorelin / GHRP-2 / GHRP-6)
• Rationale: GHRH stimulates GH pulse amplitude; secretagogue stimulates pulse frequency. Together they produce a larger GH pulse than either alone.

Tissue repair stack

• BPC-157 + TB-500
• Rationale: Proposed complementary wound-healing pathways. BPC-157 is angiogenic; TB-500 affects actin and cell migration. Often used around injury sites.

Metabolic stack

• GLP-1 agonist (semaglutide / tirzepatide) + mitochondrial peptide (MOTS-c / humanin)
• Rationale: Addressing glucose metabolism at both the hormonal and cellular level.

Risks of stacking

• Unknown interactions — Most peptide combinations have never been studied in humans.
• Confounding — If you start two compounds at once and get a side effect, you won't know which caused it.
• Overlap — Stacking two GH secretagogues (e.g. GHRP-2 and GHRP-6) is usually redundant, not additive.
• Injection burden — More compounds = more injections = more site fatigue.

How to log a stack properly

1. Stagger starts — Introduce one compound at a time, at least one week apart.
2. Log each compound independently — Dose, time, site, batch number.
3. Log side effects per compound — Not per stack.
4. Track outcomes objectively — Define success metrics before starting.

TrackPep lets you add multiple compounds to your active list and log doses for each independently, so a stack is always transparent, not muddy.